Core fucosylation and IgG function in NAIT

Blood

Volumn 123, Issue 4, 2014, Pages 463-464

  Aster, Richard H ^a,b  

^a Bloodcenter of Wisconsin   (Japan)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; HUMAN PLATELET SPECIFIC ANTIGEN 1A ANTIBODY; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; FUCOSYLATION; HUMAN; LIQUID CHROMATOGRAPHY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIALYLATION; TANDEM MASS SPECTROMETRY;

BLOOD PLATELETS; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; ISOANTIBODIES; PREGNANCY; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84893090587     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-539965     Document Type: Review

References (10)

1. Kapur R, Kustiawan I, Vestrheim A., et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood. 2014; 123(4): 471-480.
2. Nimmerjahn F, Anthony RM, Ravetch JV. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Ac (Pubitemid 47175505)
3. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci. 2009; 30(7): 356-362.
4. Sondermann P, Pincetic A, Maamary J., Lammens K, Ravetch JV. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci USA. 2013; 110(24): 9868-9872.
5. Shields RL, Lai J, Keck R., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002; 277(30): 26733-26740. (Pubitemid 34951677)
6. Shinkawa T, Nakamura K, Yamane N., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complextype oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003; 278(5): 3466-3473. (Pubitemid 36801263)
7. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 2005; 310(5753): 1510-1512. (Pubitemid 41746349)
8. Ferrara C, Grau S, Jäger C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA. 2011; 108(31): 12669-12674.
9. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009; 8(3): 226-234.
10. Peterson JA, McFarland JG, Curtis B.R., Aster RH. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol. 2013; 161(1): 3-14.